Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status (Descending)
59651-0413-50 59651-0413 HYDROCORTISONE HYDROCORTISONE 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral July 17, 2023 In Use
59651-0414-01 59651-0414 HYDROCORTISONE HYDROCORTISONE 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral July 17, 2023 In Use
59651-0415-01 59651-0415 HYDROCORTISONE HYDROCORTISONE 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral July 17, 2023 In Use
59746-0782-01 59746-0782 Prednisone Prednisone 2.5 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral June 1, 2022 In Use
59746-0782-30 59746-0782 Prednisone Prednisone 2.5 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral June 1, 2022 In Use
59746-0783-01 59746-0783 Prednisone Prednisone 50.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral June 1, 2022 In Use
60505-4512-03 60505-4512 Gefitinib Gefitinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug. 8, 2023 In Use
60505-6095-00 60505-6095 Bendamustine Hydrochloride Bendamustine Hydrochloride 25.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 19, 2023 In Use
60505-6096-00 60505-6096 Bendamustine hydrochloride Bendamustine Hydrochloride 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 19, 2023 In Use
60505-6272-01 60505-6272 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous July 1, 2023 In Use
60505-6277-00 60505-6277 CISplatin CISplatin 50.0 mg/50mL Chemotherapy Alkylating Agent Platinum Compound Intravenous June 6, 2023 In Use
63187-0526-03 63187-0526 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 1, 2019 In Use
63187-0526-04 63187-0526 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 25, 2019 In Use
63187-0526-05 63187-0526 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 1, 2019 In Use
63187-0526-06 63187-0526 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 1, 2019 In Use
62135-0772-35 62135-0772 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Aug. 29, 2023 In Use
63187-0526-10 63187-0526 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 3, 2015 In Use
63187-0526-15 63187-0526 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 1, 2016 In Use
63187-0526-20 63187-0526 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 1, 2019 In Use
63187-0526-30 63187-0526 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 3, 2015 In Use
63187-0526-12 63187-0526 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 20, 2023 In Use
63304-0116-13 63304-0116 Pazopanib Pazopanib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms Oral Oct. 20, 2023 In Use
63304-0116-30 63304-0116 Pazopanib Pazopanib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms Oral Oct. 20, 2023 In Use
63539-0051-30 63539-0051 Talazoparib Talzenna 0.5 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 21, 2023 In Use
63759-3048-01 63759-3048 Pemetrexed disodium Pemetrexed 100.0 mg/10mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 3, 2023 In Use

Found 10,000 results in 6 milliseconds — Export these results